Transition and aftercare

After a hypertensive emergency, severe asymptomatic hypertension or severe hypertension in pregnancy: when and how to switch from IV to oral drugs, the discharge regimen by the organ involved, how soon to follow up, and which secondary causes to screen for from the clinical clues (young onset, resistant hypertension, hypokalaemia, flash pulmonary oedema or creatinine rise on a RAS blocker, paroxysms, sleep apnoea, Cushingoid features, coarctation, drugs and kidney disease).

Upload a report, lab sheet or echo picture to fill this calculator automatically.

Episode

Organ involved

Revise the patient's medications

Ask before giving any drug in the ER

Clues to secondary hypertension

Tick any that apply

Transition and aftercare

IV → oral

Screen for secondary hypertension

A secondary cause is found in up to 20–40% after a hypertensive emergency

Decision guide

Switch and discharge regimen

Start oral drugs once BP and organ function have been stable for several hours (often 6–24 h); taper the infusion as they take effect, without stopping it abruptly (rebound with clevidipine, nitroprusside and esmolol).
Single-pill combination of a RAS blocker and a dihydropyridine CCB, adding a thiazide-like diuretic as needed.

Follow-up

At least monthly until the target is reached and organ damage has regressed, then long-term specialist follow-up: recurrence and cardiovascular and kidney events stay common.

Tests

Baseline for everyone after an emergency: aldosterone/renin ratio, metanephrines, kidney and renal artery imaging, urine albumin:creatinine, TSH.

Recommendations

ESC

After a hypertensive emergency: follow up at least monthly until the target is reached and HMOD regresses, then long-term specialist care
ESC/ESH 2018
Screen for secondary hypertension after a hypertensive emergency, with onset < 40, resistant or sudden worsening hypertension, or clinical clues
ESC 2024
Discharge on a single-pill combination (RAS blocker + CCB ± thiazide-like diuretic)
ESC 2024

ACC/AHA

Screen for secondary causes in new-onset or uncontrolled hypertension with clues: resistant, abrupt or onset < 30, accelerated or malignant, or unprovoked hypokalaemia
IACC/AHA 2017
Screen for primary aldosteronism in resistant hypertension and with hypokalaemia
IACC/AHA 2017
Severe asymptomatic hypertension: oral therapy and close outpatient follow-up rather than admission
AHA/ACC 2025

References